Compare BC & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BC | COGT |
|---|---|---|
| Founded | 1845 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.1B |
| IPO Year | 1994 | 2018 |
| Metric | BC | COGT |
|---|---|---|
| Price | $74.45 | $34.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 15 |
| Target Price | ★ $83.55 | $36.21 |
| AVG Volume (30 Days) | 612.6K | ★ 1.8M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.99 | N/A |
| Revenue | ★ $5,362,800,000.00 | $7,871,000.00 |
| Revenue This Year | $9.81 | N/A |
| Revenue Next Year | $5.11 | $1,733.58 |
| P/E Ratio | $36.87 | ★ N/A |
| Revenue Growth | ★ 2.40 | N/A |
| 52 Week Low | $58.66 | $11.61 |
| 52 Week High | $90.25 | $43.73 |
| Indicator | BC | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 35.04 | 37.63 |
| Support Level | $73.94 | $33.26 |
| Resistance Level | $76.55 | $37.69 |
| Average True Range (ATR) | 2.27 | 1.32 |
| MACD | -0.81 | -0.33 |
| Stochastic Oscillator | 15.82 | 13.56 |
Brunswick is a leading manufacturer in the marine recreation industry. The firm has more than 60 brands delivering products across propulsion (outboard, sterndrive, and inboard engines, propulsion-related controls, rigging, and propellers), parts, accessories, and technology, and boats (including well-known brands like Boston Whaler and Sea Ray). It also owns more than 450 Freedom Boat Club locations as well as Boateka, which facilitates transactions in the used-boat market. Brunswick's focus surrounds building the innovative marine and recreational experiences, technologies, and connections supported by quality and innovation.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.